Latest Stories for Provectus Pharmaceuticals, Inc.dlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-04-13:/organization/630272015-04-13T05:08:21-07:00<![CDATA[Provectus Biopharmaceuticals to Present at 7th Annual International Partnering Conference, ChinaBio Partnering Forum 2015, Shanghai, China]]>tag:news.dlvr.it,2015-04-08:3633302015-04-08T03:00:08-07:00
Presentation Scheduled for April 16, 2015 at 11 am Local Time
Conference Held April 15-16, 2015, at Kerry Hotel, Pudong
]]><![CDATA[Provectus Biopharmaceuticals’ Data on PV-10 to Be Presented at HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting]]>tag:news.dlvr.it,2015-04-07:3591172015-04-07T03:00:20-07:00
PV-10 Presentation Scheduled for 2:30 PM, Friday, April 10, 2015
Conference Runs April 10-11. 2015, at the Sheraton New York Times
Square Hotel
]]><![CDATA[Provectus Biopharmaceuticals Will Present at the Growth Capital Expo, Las Vegas at 1 pm PDT on Monday April 13, 2015]]>tag:news.dlvr.it,2015-04-02:3717952015-04-02T03:00:37-07:00
Conference Runs April 12-14, 2015, at Caesars Palace
]]><![CDATA[Provectus Biopharmaceuticals Will Present at the 12th Annual BIO Asia International Conference Wednesday, March 25, 2015]]>tag:news.dlvr.it,2015-03-20:3685182015-03-20T03:00:08-07:00
Conference Runs March 24-25 at Grand Hyatt in Tokyo, Japan
Provectus’ Presentation Scheduled for 3:30 PM Local Time in Drawing
Room
]]><![CDATA[Provectus Biopharmaceuticals’ Amended Protocol of PV-10 for Phase 3 Study as Treatment for Melanoma Now Available Online]]>tag:news.dlvr.it,2015-03-16:3555502015-03-16T05:35:08-07:00
Study Timeline Remains Unchanged, IRB Approval Process Begun
Minor Changes to Patient Eligibility, Endpoint Assessment and
Crossover of Patients
]]><![CDATA[Provectus Biopharmaceuticals Updates Market on Business Developments]]>tag:news.dlvr.it,2015-03-12:3645862015-03-12T05:21:08-07:00
Amended Phase 3 Protocol Submitted to FDA
Enrollment Begun in PH-10 Mechanism of Action Study
Enrollment Completed in PV-10 Immunology Mechanism of Action Trial
]]><![CDATA[Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office]]>tag:news.dlvr.it,2015-03-12:3698322015-03-12T05:12:14-07:00Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office]]><![CDATA[Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Results]]>tag:news.dlvr.it,2015-03-12:3571762015-03-12T04:51:07-07:00PROVECTUS BIOPHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND
YEAR END 2014 RESULTS]]><![CDATA[Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015]]>tag:news.dlvr.it,2015-02-24:3340132015-02-24T03:00:40-08:00
Call to be Webcast, Available for Digital Replay
]]><![CDATA[Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition]]>tag:news.dlvr.it,2015-02-18:3344072015-02-18T03:00:14-08:00
Conference Runs March 3-4 at Hilton Zurich Airport Hotel, Switzerland
Presentation Scheduled for March 3, 2015
]]><![CDATA[Provectus Biopharmaceuticals Will Present at 17th Annual BIO CEO And Investor Conference Tuesday, February 10, 2015]]>tag:news.dlvr.it,2015-02-10:3413992015-02-10T03:01:00-08:00
Conference Runs February 9-10 at Waldorf Astoria
Provectus’ Presentation Scheduled for 3 PM in Duke of Windsor Room
]]><![CDATA[Provectus Biopharmaceuticals Met with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study]]>tag:news.dlvr.it,2015-02-09:3490952015-02-09T03:01:24-08:00
FDA allows Provectus to go forward on Phase 3
]]><![CDATA[Provectus Biopharmaceutical’s PV-10 Featured in Article by Sanjiv Agarwala in Current Opinion in Oncology]]>tag:news.dlvr.it,2015-02-06:3501952015-02-06T03:00:07-08:00
March Issue Available On-Line Now
]]><![CDATA[Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis]]>tag:news.dlvr.it,2015-01-29:3374892015-01-29T03:00:35-08:00Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis]]><![CDATA[Provectus Biopharmaceuticals’ Novel Synthesis Patent Application Allowed by Chinese Patent Office]]>tag:news.dlvr.it,2015-01-26:3361162015-01-26T03:00:28-08:00PROVECTUS BIOPHARMACEUTICALS’ NOVEL SYNTHESIS PATENT APPLICATION ALLOWED BY CHINESE PATENT OFFICE]]>
Presentation Scheduled for April 16, 2015 at 11 am Local Time
Conference Held April 15-16, 2015, at Kerry Hotel, Pudong
]]>
PV-10 Presentation Scheduled for 2:30 PM, Friday, April 10, 2015
Conference Runs April 10-11. 2015, at the Sheraton New York Times
Square Hotel
]]>
Conference Runs April 12-14, 2015, at Caesars Palace
]]>
Conference Runs March 24-25 at Grand Hyatt in Tokyo, Japan
Provectus’ Presentation Scheduled for 3:30 PM Local Time in Drawing
Room
]]>
Study Timeline Remains Unchanged, IRB Approval Process Begun
Minor Changes to Patient Eligibility, Endpoint Assessment and
Crossover of Patients
]]>
Amended Phase 3 Protocol Submitted to FDA
Enrollment Begun in PH-10 Mechanism of Action Study
Enrollment Completed in PV-10 Immunology Mechanism of Action Trial
]]>
Provectus Biopharmaceuticals Awarded PH-10 Patent by U.S. Patent and Trademark Office]]>
PROVECTUS BIOPHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND
YEAR END 2014 RESULTS]]>
Call to be Webcast, Available for Digital Replay
]]>
Conference Runs March 3-4 at Hilton Zurich Airport Hotel, Switzerland
Presentation Scheduled for March 3, 2015
]]>
Conference Runs February 9-10 at Waldorf Astoria
Provectus’ Presentation Scheduled for 3 PM in Duke of Windsor Room
]]>
FDA allows Provectus to go forward on Phase 3
]]>
March Issue Available On-Line Now
]]>
Provectus Biopharmaceuticals Begins Recruitment for Phase 2 Mechanism of Action Clinical Trial Of PH-10 For Psoriasis]]>
PROVECTUS BIOPHARMACEUTICALS’ NOVEL SYNTHESIS PATENT APPLICATION ALLOWED BY CHINESE PATENT OFFICE]]>